[PDF] Top 20 El corpus paral·lel del Diari Oficial de la Generalitat de Catalunya

... with basal-bolus ...with IDegLira were reductions in BMI and lower rates of severe and non-severe ...with IDegLira. IDegLira was associated with increased direct costs over patient ... See full document

... a cost-effective option compared to NPH insulin when the avoidance of severe hypoglycemia reduced by ...NPH insulin, because the ICER value may no longer be a cost- effective ...the ... See full document

... National Health Service ...patient’s insulin regimen, providing glycemic control over the course of the day (as opposed to “bolus” insulin, which is administered at mealtimes in ... See full document

... Daily IDegLira dose data were obtained from the IDegLira arm of DUAL II, to which the treatment effect reported by the indirect treatment comparison was applied to obtain the daily dose for ...and ... See full document

... by patients, and were therefore not considered in this ...variability versus glargine U100, fewer SMBG tests are needed for titration and maintenance with degludec [20, 22, ...be cost saving for the ... See full document

... of diabetes management, as sup- ported by robust observational and experimental ...of type 2 diabetes mellitus provides not only glycemic control, but also cardiovascular ...safety. ... See full document

... Two Thomson Reuters MarketScan ® research data- bases were used in this study: the Commercial Claims and Encounters (Commercial) database and the Medi- care Supplemental and Coordination of Benefits (Medicare ... See full document

... the patients of regime C took lesser time and had an earlier recovery as compared to those who received the other ...mean cost of the insulin regimes which were used during the peri-operative period, ... See full document

... of insulin degludec/liraglutide plus metformin is non-inferior to continued titration of the basal-bolus association of insulin glargine (once per day) and insulin aspart ( ≤ 4 times ... See full document

... treatment cost and change of daily treatment cost at month-6 increased with the growing of baseline HbA1c level and prolonged diabetes ...longer diabetes duration (≥15 years) had lower HbA1c ... See full document

... adult patients with type 2 DM who were receiving basal-bolus insulin therapy (requiring ≥42 units/day of basal insulin) for at least one year ...of insulin ... See full document

... daily insulin dose was therefore the same for the two ...plasma insulin and glucose infusion rate (GIR – the amount of glucose needed to maintain the clamp level fol- lowing the insulin injections) ... See full document

... long-acting insulin analogue produced by recombinant DNA technology that involves the deletion of the amino acid threonine at the B-30 locus and the acylation of a 14-carbon fatty acid called myristic acid to ... See full document

... The only potential treatment- related death was a myocardial infarction reported in the glargine group in Study B. In Study A, one event of sudden cardiac death was reported in the degludec group, but this occurred 11 ... See full document

... of patients were receiving detemir once daily and twice daily, respectively; 41% and 59% were receiv- ing NPH once daily and twice daily, ...NPH insulin (P = ... See full document

... 1, 2, and 3 trials confirmed no differ- ence in mean change in A1C between Gla-300 and Gla-100, as seen in the individual studies ...of patients experiencing ≥ 1 confirmed or severe hypoglycemic event at ... See full document

... the basal insulin compo- nent, patients requiring less than the minimum starting doses (iGlarLixi, 15 units; IDegLira, 16 units) or more than the maximum doses (iGlarLixi, 60 units; ... See full document

... of type 2 diabetes, GLP-1 receptor agonists can be introduced at multiple stages throughout type 2 diabetes treatment ... See full document

... in patients already on insulin, but was not affected in insulin-naïve patients with type 2 diabetes (Table ...in patients assigned glargine-300 compared to those ... See full document

... 1, 2, and 3, the main secondary end point was the percent- age of participants with one or more confirmed nocturnal ( ≤ ...in type 1 and type 2 diabetes” ...change, insulin dose, ... See full document